Weekly Analysts’ Ratings Updates for BioMarin Pharmaceutical (BMRN)

BioMarin Pharmaceutical (NASDAQ: BMRN) recently received a number of ratings updates from brokerages and research firms:

• 3/25/2026 – BioMarin Pharmaceutical was upgraded by Truist Financial Corporation to “strong-buy”.
• 3/16/2026 – BioMarin Pharmaceutical had its “outperform” rating reaffirmed by Wolfe Research.
• 3/12/2026 – BioMarin Pharmaceutical had its “buy” rating reaffirmed by Jefferies Financial Group Inc.. They now have a $103.00 price target on the stock.
• 3/11/2026 – BioMarin Pharmaceutical had its price target lowered by Bank of America Corporation from $97.00 to $85.00. They now have a “buy” rating on the stock.
• 3/3/2026 – BioMarin Pharmaceutical had its price target raised by Barclays PLC from $80.00 to $105.00. They now have an “overweight” rating on the stock.
• 3/2/2026 – BioMarin Pharmaceutical was given a new $105.00 price target by Loop Capital.
• 2/26/2026 – BioMarin Pharmaceutical had its price target raised by Canaccord Genuity Group Inc. from $98.00 to $104.00. They now have a “buy” rating on the stock.
• 2/25/2026 – BioMarin Pharmaceutical had its price target raised by Sanford C. Bernstein from $90.00 to $94.00. They now have an “outperform” rating on the stock.
• 2/25/2026 – BioMarin Pharmaceutical had its price target lowered by Guggenheim from $106.00 to $86.00. They now have a “buy” rating on the stock.
• 2/25/2026 – BioMarin Pharmaceutical had its price target lowered by HC Wainwright from $60.00 to $55.00. They now have a “neutral” rating on the stock.
• 2/24/2026 – BioMarin Pharmaceutical was given a new $68.00 price target by Stifel Nicolaus.
• 2/24/2026 – BioMarin Pharmaceutical had its price target lowered by Oppenheimer Holdings, Inc. from $98.00 to $95.00. They now have an “outperform” rating on the stock.
• 2/18/2026 – BioMarin Pharmaceutical had its price target raised by Wells Fargo & Company from $70.00 to $75.00. They now have an “overweight” rating on the stock.
• 2/6/2026 – BioMarin Pharmaceutical had its price target lowered by Piper Sandler from $122.00 to $84.00. They now have an “overweight” rating on the stock.
• 1/28/2026 – BioMarin Pharmaceutical is now covered by Barclays PLC. They set an “overweight” rating and a $80.00 price target on the stock.

Insider Activity at BioMarin Pharmaceutical

In other news, EVP Gregory R. Friberg sold 6,326 shares of the firm’s stock in a transaction that occurred on Thursday, February 26th. The shares were sold at an average price of $60.38, for a total transaction of $381,963.88. Following the transaction, the executive vice president directly owned 37,578 shares in the company, valued at approximately $2,268,959.64. This trade represents a 14.41% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Charles Greg Guyer sold 16,486 shares of BioMarin Pharmaceutical stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $60.46, for a total transaction of $996,743.56. Following the completion of the transaction, the executive vice president directly owned 79,953 shares in the company, valued at $4,833,958.38. The trade was a 17.09% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 0.85% of the company’s stock.

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.